within Pharmacolibrary.Drugs.ATC.V;

model V03AF07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 7.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,
    adminCount     = 1,
    Vd             = 0.00023,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Rasburicase is a recombinant urate oxidase enzyme used primarily for the management of hyperuricemia associated with tumor lysis syndrome (TLS) in patients undergoing cancer chemotherapy. It is approved for clinical use in several countries, typically as an intravenous agent and is especially valuable in pediatric and adult patients at high risk for TLS.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult and pediatric cancer patients with hyperuricemia undergoing intravenous rasburicase therapy.</p><h4>References</h4><ol><li><p>Easton, J, et al., &amp; Jarvis, B (2001). Rasburicase. <i>Paediatric drugs</i> 3(6) 433–439. DOI:<a href=&quot;https://doi.org/10.2165/00128072-200103060-00004&quot;>10.2165/00128072-200103060-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11437188/&quot;>https://pubmed.ncbi.nlm.nih.gov/11437188</a></p></li><li><p>Cairo, MS (2002). Prevention and treatment of hyperuricemia in hematological malignancies. <i>Clinical lymphoma</i> 3 Suppl 1 S26–S31. DOI:<a href=&quot;https://doi.org/10.3816/clm.2002.s.012&quot;>10.3816/clm.2002.s.012</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12521386/&quot;>https://pubmed.ncbi.nlm.nih.gov/12521386</a></p></li><li><p>Kikuchi, A, et al., &amp; Tsukimoto, I (2009). A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. <i>International journal of hematology</i> 90(4) 492–500. DOI:<a href=&quot;https://doi.org/10.1007/s12185-009-0402-6&quot;>10.1007/s12185-009-0402-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19701676/&quot;>https://pubmed.ncbi.nlm.nih.gov/19701676</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V03AF07;
